Caitlin Costello, MD, shares insights on the role of minimal residual disease (MRD) assessment in the multiple myeloma treatment process, including its impact on induction therapy and disease monitoring.
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.